The Short-acting Insulin Market Is Driven By Growing Prevalence Of Diabetes

By Author: colin
Total Articles: 197
Comment this article

The short-acting insulin market comprises products that are used to control blood sugar levels in patients suffering from diabetes. Short-acting insulin products work quickly and their effects last for a short duration, typically between 3 to 6 hours. Some of the commonly used short-acting insulin products include insulin lispro, insulin aspart and insulin glulisine. They provide faster-acting relief from high blood sugar as compared to traditional human insulin and are primarily prescribed for managing post-meal blood glucose levels or correcting hyperglycemia. Rising prevalence of diabetes worldwide is a key driver of the short-acting insulin market.
The Short-Acting Insulin Market is estimated to be valued at US$ 9.5 Bn in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the short-acting insulin market are Eli Lilly and Company, Novo Nordisk, Sanofi, Biocon, Adocia. Eli Lilly and Company and Novo Nordisk collectively account for over 70% share of the Short-Acting Insulin Market.
Growing prevalence of diabetes across the globe ...
... especially in developing nations is fueling the demand for short-acting insulin therapy. According to International Diabetes Federation, over 537 million adults were living with diabetes in 2021 worldwide and the numbers are expected to rise to over 700 million by 2045.
Major companies in the market are focusing on geographical expansion through acquisition of regional players and establishment of manufacturing & distribution networks in emerging markets of Asia Pacific and Middle East & Africa to tap the growth opportunities in these regions.
Market Drivers
One of the key drivers of the short-acting insulin market is the growing global burden of diabetes. According to WHO, diabetes was the ninth leading cause of death in 2019 responsible for 1.5 million deaths globally. Rising geriatric population, increasing rates of obesity, sedentary lifestyles are some of the major factors responsible for surging diabetes cases worldwide. This is expected to propel the demand for short-acting insulin for diabetes management over the forecast period.
Geopolitical Impact On Short-Acting Insulin Market Growth
The short-acting insulin market is witnessing significant changes due to the ongoing geopolitical conflicts and economic turmoil across various regions. The supply chain disruptions caused by the Russia-Ukraine war have adversely impacted the availability of raw materials for insulin production in Eastern Europe. This is hampering the overall production volumes and distribution networks of leading manufacturers. Moreover, sanctions on Russia are limiting the market access and exports of insulin to Central Asia and parts of Europe, thereby restraining revenue growth. The volatile economic conditions and currency fluctuations in some developing nations are also posing challenges in pricing and affordability of insulin therapy.
To ensure continuous supply and expand reach, market players must focus on establishing alternate manufacturing hubs, diversifying raw material sources, and optimizing global logistic chains. Collaborating with regional pharma companies and focusing on domestic production can aid in minimizing overdependence on key suppliers. Adopting localized pricing and reimbursement strategies customized for different income groups will further help in improving accessibility and adherence to treatment. Meanwhile, developing ultra-long-acting formulations and innovative insulin delivery devices can facilitate better management of diabetes in remote locations with limited healthcare access.
Concentration In Key Regions
In terms of value, North America remains the dominant region for the short-acting insulin market, accounting for over 35% revenue share as of 2024. This can be attributed to the rising prevalence of type 1 diabetes, availability of favorable reimbursements, and growing adoption of advanced insulin therapies. Europe is the second largest regional market, driven by increasing public health awareness about diabetes management in the community. On the other hand, Asia Pacific is emerging as the fastest growing regional sector and is expected to expand at a CAGR of around 6.5% during the forecast period. This growth can be attributed to improving healthcare infrastructure, growing medical tourism, and rising research focus on affordable insulin therapies.
Fastest Growing Region
Asia Pacific is poised to offer the most lucrative opportunities for stakeholders in the short-acting insulin market. factors such as the rapidly growing diabetic population, increasing medical spending, rising health awareness, growing focus towards local manufacturing of insulin, and favorable regulatory assistance are fueling the demand across various Asian countries. Moreover, India, China, and South East Asian countries are witnessing expansion of Medicare coverage for diabetes treatment. This is increasing the affordability and accessibility of insulin products in rural and financially backward communities. All these favorable macro factors are contributing to the accelerated growth momentum of the Asia Pacific region.

Get more insights on this topic: https://savagesoulhub33.blogspot.com/2024/09/short-acting-insulin-market-is.html

Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Short-Acting Insulin Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Short-Acting Insulin Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Short-Acting Insulin Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Short-Acting Insulin Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Short-Acting Insulin Market vendors
FAQ’s
Q.1 What are the main factors influencing the Short-Acting Insulin Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Short-Acting Insulin Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Short-Acting Insulin Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it